The mission of the Center for Cancer Genome Discovery (CCGD) is to advance precision cancer medicine by developing new technologies for cancer genome analysis and to provide basic, translational, and clinical investigators with access to these technologies.
We focus on the discovery of genomic alterations in human cancer and evaluation of their clinical significance for informing diagnosis and treatment. We use Illumina next-generation sequencing platforms to detect the full range of genomic alterations, including:
An integral aspect of the Center's mission is working toward more effective clinical trial designs, in which patients with similar genetically defined cancers will receive drugs designed to target specific genetic aberrations. In addition to the principal areas indicated above, CCGD is available to assist collaborators with funding (e.g., grant submissions), experimental design, and coordination of each project through the appropriate channels.
Our research and development group continually evaluates and develops next-generation sequencing technologies for both research and clinical use. From our inception, we have collaborated with research investigators to develop new genome discovery tools, and we welcome investigators and clinicians to contact us about new avenues of research that we can help facilitate. We can provide a host of services that include project design, sequencing library construction, custom design and validation of hybrid capture gene panels for targeted sequencing, and bioinformatic analysis.
CCGD: Aaron ThornerProfile: Elizabeth GarciaBioinformatics: Matthew Ducar
For general questions:617-582-7253 email@example.com